JNJ-53773187

JNJ-53773187 is a small molecule drug developed by Johnson & Johnson and its subsidiary Janssen-Cilag International NV. It has been investigated in early-phase clinical trials, specifically for pharmacokinetic studies in healthy male subjects. The available data indicate that it was administered as a single oral dose of 100 micrograms under fasted conditions to assess its pharmacokinetics[1][2]. There is no evidence of FDA or EMA approval, nor are there any known active therapeutic indications or detailed mechanism of action publicly disclosed as of the latest updates[2][3]. Its development status appears limited to Phase 1 clinical evaluation.